Results from the phase 1b/2 SGNTUC-024 study: Assessment of tucatinib, trastuzumab, and FOLFOX for HER2+ GI cancers.
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Haeseong Park, Tanios S. Bekaii-Saab, Sunnie S. Kim, Michael J. Pishvaian, Yu Sunakawa, Suneel Deepak Kamath, Akihito Kawazoe, Kei Muro, David Bing Zhen, Hidekazu Hirano, Erika Maestas, Patrick Grierson, Naotoshi Sugimoto, Kensei Yamaguchi, Michelle Ubowski, Qianwen Tan, David E. Adelberg, John H Strickler
Institutions: Dana-Farber Cancer Institute, Mayo Clinic, Mayo Clinic in Arizona, Mayo Clinic Comprehensive Cancer Center (Arizona), University of Colorado Cancer Center, Johns Hopkins University, St. Marianna University School of Medicine, Cleveland Clinic, National Cancer Center Hospital East, Aichi Cancer Center, Aichi Cancer Center Hospital, University of Washington, Fred Hutch Cancer Center, National Cancer Center Hospital, UNM Comprehensive Cancer Center, Washington University in St. Louis, Osaka International Cancer Institute, The Cancer Institute Hospital, Japanese Foundation For Cancer Research, Seagen (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Duke Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Seagen
OpenAlex ID: W4391095188